| Filed On | Filing |
|---|---|
| 13 Nov 2026 | 8-K: Other Events |
| 06 Nov 2026 |
8-K: Other Events
Cooley llp 10265 Science Center Drive San Diego, CA 92121t: (858) 550-6000 f: (858) 550-6420 cooley.com |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint; study-related activities initiated. |
| 27 Oct 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
aTyr Pharma, Inc. (the “Corporation”), a corporation organized and existing under the laws of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies as follows: |
| 16 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On October 16, 2026, aTyr Pharma, Inc. (the “Company”) held its 2026 Special Meeting of Stockholders (the “Special Meeting”). As of September 4, 2026, the record date for the Special Meeting (the “Record Date”), 98,087,425 shares of the ... |
| 24 Sep 2026 |
8-K: Other Events
On September 24, 2026, aTyr Pharma, Inc. (the Company) announced that it has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a Phase 3 study of its lead therapeutic candidate, efzofitimod, in patien... |
| 07 Aug 2026 |
8-K: Results of Operations and Financial Condition
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD |
| 31 Jul 2026 |
8-K: Termination of a Material Definitive Agreement
This TERMINATION AGREEMENT (this “Agreement”) is made and entered into as of July 30, 2026 (“Execution Date”), by and between aTyr Pharma, Inc., a Delaware corporation, having its principal place of business at 10240 Sorrento Valley Road... |
| 08 Jun 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed, on December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Compa... |
| 01 Jun 2026 |
8-K: Regulation FD Disclosure
aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond June 2026 © 2026 aTyr Pharma Exhibit 99.1 |
| 15 May 2026 |
8-K: Results of Operations and Financial Condition
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. |
| 11 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
aTyr Pharma Advancing tRNA synthetase biology Efzofitimod in Pulmonary Sarcoidosis and Beyond May 11, 2026 © 2026 aTyr Pharma Exhibit 99.1 |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
Company scheduled to meet with the FDA in mid-April 2026 to review the results of the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis. |
| 05 Dec 2025 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On December 4, 2025, aTyr Pharma, Inc. (the “Company”) received a deficiency notice (the “Notice”) from the listing qualifications staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 ... |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
Results reported for Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis. |
| 15 Sep 2025 |
8-K: Other Events
A New Approach to Interstitial Lung Disease Topline Results for Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis September 15, 2025 Exhibit 99.1 |
| 07 Aug 2025 |
8-K: Material Impairments
Last patient visit completed in Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis; topline results expected in mid-September 2025. |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis on track for the third quarter of 2025. |
| 06 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a D... |
| 13 Mar 2025 |
8-K: Results of Operations and Financial Condition
Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025. |
Loading...